ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5004ometendo-5004Research ArticleСтатьиArticlesОпыт применения препарата Редуксин (сибутрамин) у больных с метаболическим синдромомOpyt primeneniya preparata Reduksin (sibutramin) u bol'nykh s metabolicheskim sindromomButrovaS A-BerkovskayaM A-KomshilovaK A-20071512200744№4 (2007)3439Copyright © Butrova S.A., Berkovskaya M.A., Komshilova K.A., 20072007Butrova S.A., Berkovskaya M.A., Komshilova K.A.Butrova S.A., Berkovskaya M.A., Komshilova K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5004ReferencesБутрова С.А. Современная фармакотерапия ожирения. Consilium Medicum. 2004;06(9):669-674.Бутрова С.А. Современная фармакотерапия ожирения. Consilium Medicum. 2004;06(9):669-674.Волкова Г.Е., Романцова Т.И., Вознесенская Т.Г., Роик О.В. Пищевое поведение у пациентов с ожирением. Ожирение и метаболизм. 2007;2:17-21.Волкова Г.Е., Романцова Т.И., Вознесенская Т.Г., Роик О.В. Пищевое поведение у пациентов с ожирением. Ожирение и метаболизм. 2007;2:17-21.Ожирение: этиология, патогенез, клинические аспекты: Руководство для врачей / под ред. И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агентство», 2006. 456 с.Ожирение: этиология, патогенез, клинические аспекты: Руководство для врачей / под ред. И.И. Дедова, Г.А. Мельниченко. М.: ООО «Медицинское информационное агентство», 2006. 456 с.Avenell A., Brown T.J., McGee M.A., Campbell M.K., Grant A.M., Broom J., Jung R.T., Smith W.C. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004 Aug;17(4):293-316.Avenell A., Brown T.J., McGee M.A., Campbell M.K., Grant A.M., Broom J., Jung R.T., Smith W.C. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004 Aug;17(4):293-316.Baranowska B., Woliska-Witort E., Martyska L., Chmielowska M., Mazurczak-Pluta T., Boguradzka A., Baranowska-Bik A. Sibutramine therapy in obese women effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol Lett. 2005 Dec;26(6):675-9.Baranowska B., Woliska-Witort E., Martyska L., Chmielowska M., Mazurczak-Pluta T., Boguradzka A., Baranowska-Bik A. Sibutramine therapy in obese women effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol Lett. 2005 Dec;26(6):675-9.Di Francesco V., Sacco T., Zamboni M., Bissoli L., Zoico E., Mazzali G., Minniti A., Salanitri T., Cancelli F., Bosello O. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann Nutr Metab. 2007;51(1):75-81.Di Francesco V., Sacco T., Zamboni M., Bissoli L., Zoico E., Mazzali G., Minniti A., Salanitri T., Cancelli F., Bosello O. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann Nutr Metab. 2007;51(1):75-81.Finer N., Bloom S.R., Frost G.S., Banks L.M., Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, doubleblind, placebo-controlled study. Diabetes Obes Metab. 2000 Apr;2(2):105-12.Finer N., Bloom S.R., Frost G.S., Banks L.M., Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, doubleblind, placebo-controlled study. Diabetes Obes Metab. 2000 Apr;2(2):105-12.James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., Saris W.H., Van Gaal L.F. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000 Dec 23-30;356(9248):2119-25.James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., Saris W.H., Van Gaal L.F. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000 Dec 23-30;356(9248):2119-25.Lоpez-Alvarenga J.C., Vargas J.A., Schneider-Ehrenberg O.P., Comuzzie A.G., Gonzalez J., Martinez J.L. Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally. Gac Med Mex. 2007 Mar-Apr;143(2):109-14.Lоpez-Alvarenga J.C., Vargas J.A., Schneider-Ehrenberg O.P., Comuzzie A.G., Gonzalez J., Martinez J.L. Patients with type III obesity given sibutramine 15 mg/day lose weight in amounts proportional to those in types I and II, but waist circumferences does not decrease proportionally. Gac Med Mex. 2007 Mar-Apr;143(2):109-14.McMahon F.G., Fujioka K., Singh B.N., Mendel C.M., Rowe E., Rolston K., Johnson F., Mooradian A.D. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000 Jul 24;160(14):2185-91.McMahon F.G., Fujioka K., Singh B.N., Mendel C.M., Rowe E., Rolston K., Johnson F., Mooradian A.D. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000 Jul 24;160(14):2185-91.Nisoli E., Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000 Oct;1(2):127-39.Nisoli E., Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000 Oct;1(2):127-39.Phelan S., Wadden T.A., Berkowitz R.I., Sarwer D.B., Womble L.G., Cato R.K., Rothman R. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007 Sep;31(9):1442-8.Phelan S., Wadden T.A., Berkowitz R.I., Sarwer D.B., Womble L.G., Cato R.K., Rothman R. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007 Sep;31(9):1442-8.Sabuncu T., Harma M., Harma M., Nazligul Y., Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril. 2003 Nov;80(5):1199-204.Sabuncu T., Harma M., Harma M., Nazligul Y., Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril. 2003 Nov;80(5):1199-204.Sabuncu T., Ucar E., Birden F., Yasar O. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab. 2004 Apr;17(2):103-7.Sabuncu T., Ucar E., Birden F., Yasar O. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab. 2004 Apr;17(2):103-7.Saraz F., Pehlivan M., Celebi G., Saygili F., Yilmaz C., Kabalak T. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther. 2006 Nov-Dec;23(6):1016-29.Saraz F., Pehlivan M., Celebi G., Saygili F., Yilmaz C., Kabalak T. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther. 2006 Nov-Dec;23(6):1016-29.Scheen A.J. Results of obesity treatment. Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 1):163-70.Scheen A.J. Results of obesity treatment. Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 1):163-70.Scholze J. Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsch Med Wochenschr. 2002 Mar 22;127(12):606-10.Scholze J. Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsch Med Wochenschr. 2002 Mar 22;127(12):606-10.Tong N.W., Ran X.W., Li Q.F., Tang B.D., Li R., Yang F.Y., Liu Y.P., Li X.J. Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial. Zhonghua Nei Ke Za Zhi. 2005 Sep;44(9):659-63.Tong N.W., Ran X.W., Li Q.F., Tang B.D., Li R., Yang F.Y., Liu Y.P., Li X.J. Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial. Zhonghua Nei Ke Za Zhi. 2005 Sep;44(9):659-63.Toubro S., Hansen D.L., Hilsted J.C., Porsborg P.A., Astrup A.V. STORM Study Group. The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial. Ugeskr Laeger. 2001 May 21;163(21):2935-40.Toubro S., Hansen D.L., Hilsted J.C., Porsborg P.A., Astrup A.V. STORM Study Group. The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial. Ugeskr Laeger. 2001 May 21;163(21):2935-40.Vettor R., Serra R., Fabris R., Pagano C., Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005 Apr;28(4):942-9.Vettor R., Serra R., Fabris R., Pagano C., Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005 Apr;28(4):942-9.Wirth A. Sustained weight reduction after cessation of obesity treatment with Sibutramine. Dtsch Med Wochenschr. 2004 Apr 30;129(18):1002-5.Wirth A. Sustained weight reduction after cessation of obesity treatment with Sibutramine. Dtsch Med Wochenschr. 2004 Apr 30;129(18):1002-5.
The authors declare that there are no conflicts of interest present.